Drug Profile
Research programme: obesity therapy - ATON/Illumina
Alternative Names: Obesity therapy research programme - ATON/IlluminaLatest Information Update: 28 Sep 2023
Price :
$50
*
At a glance
- Originator Hybrigenics; Illumina
- Developer Illumina
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Obesity